Viridian Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €260.19K -3.8% -€232.57M +13.6% -89,387.1% -140 pp -€199.71M +26.5% -76,757.6% -180 pp
    €270.53K -82.3% -€204.82M +89.5% -75,711.5% -690 pp -€157.90M +97.0% -58,366.9% -530 pp
    €1.53M -40.2% -€108.08M +58.0% -7,079.2% -44 pp -€80.16M +71.5% -5,250.6% -34 pp
    €2.55M +182.2% -€68.42M -28.4% -2,680.3% +79 pp -€46.73M +82.4% -1,830.7% +10 pp
    €904.63K -76.5% -€95.62M +161.6% -10,569.9% -96 pp -€25.62M -17.3% -2,832.1% -20 pp
    €3.84M -46.8% -€36.55M +29.7% -950.9% -5.6 pp -€30.99M +36.3% -806.4% -4.9 pp
    €7.22M +109.5% -€28.18M +23.4% -390.0% +2.7 pp -€22.74M -5.5% -314.8% +3.8 pp
    €3.45M +20.0% -€22.84M +109.2% -662.3% -2.8 pp -€24.06M +286.3% -697.5% -4.8 pp
    €2.87M +31.5% -€10.92M +11.9% -379.8% +0.67 pp -€6.23M +6.7% -216.6% +0.50 pp
    €2.19M -41.3% -€9.76M +43.6% -446.3% -2.6 pp -€5.84M +248.0% -266.9% -2.2 pp
    €3.72M +0.1% -€6.80M +265.3% -182.6% -1.3 pp -€1.68M +67.4% -45.1% -0.18 pp
    €3.72M -2.0% -€1.86M -70.1% -50.0% +1.1 pp -€1.00M -81.0% -26.9% +1.1 pp
    €3.80M -€6.21M -163.7% -€5.27M -138.9%

    Notifications